Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males.

Abstract

This study investigated the stimulatory potential of a superactive gonadotropin releasing hormone analogue in idiopathic oligozoospermia. In a double-blind trial, 19 men were randomized to receive buserelin (D-Ser(TBU)6-GnRH ethylamide) in one of two dosages or saline, twice weekly, for twelve weeks. Treatment did not lead to a significant increase in serum concentrations of the pituitary gonadotropins or in sperm concentrations. However, in the dosages and schedules investigated, there was no inhibitory effect of the analogue. Further assessment of this approach is suggested.

• Authors: D F Badenoch, J Waxman, L Boorman, B Sidhu, H D Moore, W V Holt, J P Blandy
• Journal: Acta endocrinologica (Acta Endocrinol (Copenh)) Vol. 117 Issue 2 Pg. 265-7 (Feb 1988) ISSN: 0001-5598 [Print] Denmark
• PMID: 3132792 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Testosterone
• Luteinizing Hormone
• Follicle Stimulating Hormone
• Buserelin

Topics

• Buserelin (administration & dosage)
• Clinical Trials as Topic
• Double-Blind Method
• Follicle Stimulating Hormone (blood)
• Humans
• Luteinizing Hormone (blood)
• Male
• Oligospermia (drug therapy)
• Random Allocation
• Testosterone (blood)